Literature DB >> 10206156

MRI characteristics of midbrain tumours.

B Sun1, C C Wang, J Wang.   

Abstract

We diagnosed 60 cases of midbrain tumours by MRI between 1993 to 1997. There were 39 males and 21 females, aged 2-64 years, mean 25.6 years. We found 38 patients with true intramedullary mid-brain tumours, 11 predominantly in the tectum, 20 in the tegmentum and 7 with a downward extension to the pons; there were 7 within the cerebral aqueduct. There were 22 patients with infiltrating midbrain tumours extending from adjacent structures, 11 cases each from the thalamus and pineal region. All patients received surgical treatment. Gross total resection was achieved in 42 cases, subtotal (> 75 %) resection in 18. Pathological diagnoses included 16 low-grade and 15 high-grade astrocytomas; 5 oligodendroastrocytomas; 2 ependymomas; 11 glioblastomas; and 11 pineal parenchymal or germ-cell tumours. Midbrain tumours are a heterogeneous group of neoplasms, with wide variation in clinical and MRI features, related to the site and type of tumour. MRI not only allows precise analysis of their growth pattern, but also can lead to a correct preoperative diagnosis in the majority of cases.

Entities:  

Mesh:

Year:  1999        PMID: 10206156     DOI: 10.1007/s002340050723

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  3 in total

Review 1.  Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors.

Authors:  Adam L Green; Mark W Kieran
Journal:  Curr Oncol Rep       Date:  2015-03       Impact factor: 5.075

Review 2.  Posterior fossa tumors in children: developmental anatomy and diagnostic imaging.

Authors:  Charles Raybaud; Vijay Ramaswamy; Michael D Taylor; Suzanne Laughlin
Journal:  Childs Nerv Syst       Date:  2015-09-09       Impact factor: 1.475

3.  Primary midbrain cystic germinoma mimicking glioma: a case with neuroendoscopic biopsy.

Authors:  Masafumi Uchino; Daisuke Haga; Toshiaki Mito; Tohru Kuramitsu; Noriko Nakamura
Journal:  J Neurooncol       Date:  2006-03-24       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.